Medscape is available in 5 Language Editions – Choose your Edition here.


Cough, Cold, and Allergy Preparation Toxicity Treatment & Management

  • Author: Laleh Gharahbaghian, MD; Chief Editor: Timothy E Corden, MD  more...
Updated: Dec 29, 2015

Approach Considerations

Some states have laws mandating the reporting of child abuse, suspicion of child abuse, and neglect. If the history of ingestion is suspicious, reporting may be necessary.

Paramedics should follow set protocols for gastric decontamination, hypotension, and seizures; symptomatic patients should be transported rapidly with intravenous access and cardiac monitoring. Benzodiazepines may be used for agitation or seizures.

In the emergency department (ED), basic tenets of emergency care should dictate therapy. Perform bedside determinations of glucose for patients with altered levels of conscious and treat with intravenous dextrose, if appropriate. For hypotensive patients, administer 0.9% sodium chloride solution or lactated Ringer solution as boluses. Dopamine, or other cardiac pressor, may be titrated to achieve an acceptable blood pressure.

Administer activated charcoal to patients who are cooperative, have a good gag reflex, and can take liquids by mouth safely. Perform endotracheal intubation before instillation of activated charcoal for patients with significant CNS depression and an unprotected airway. The clinician should be aware that a severely toxic patient can experience seizures and aspirate charcoal.

Gastric emptying has not proven beneficial if the patient presents more than 1 hour postingestion, although case reports involving anticholinergic agents have demonstrated erratic absorption and repeated worsening of anticholinergic symptoms over 9 days. Ipecac syrup is not recommended in the ED because it may delay the administration of activated charcoal and seizures may occur at any time, with the possibility of aspiration. Repeated doses of activated charcoal may prevent continued absorption, but the development of ileus generally limits its use.

Anticholinergic-induced delirium ranges from mild confusion to severe agitation with associated hyperthermia and rhabdomyolysis. The use of chemical and physical restraints often is necessary to prevent patients from harming themselves or others. Controlling muscular activity is crucial in severely agitated patients, because agitation may exacerbate muscle injury, acidosis, rhabdomyolysis, and hyperthermia.

Although benzodiazepines often are considered first-line agents, physostigmine is safe and effective for the treatment of antihistamine-induced agitated delirium, provided that the electrocardiogram (ECG) does not demonstrate conduction disturbances (ie, PR and QRS prolongation). One study suggests that physostigmine is more effective and just as safe as benzodiazepines for controlling antihistamine-induced agitated delirium.[72] Physostigmine also reverses peripheral anticholinergic signs and symptoms.

Considering that patients with anticholinergic symptoms usually fare well with supportive therapy alone, physostigmine is indicated only in the following limited circumstances:

  • Single-drug (anticholinergic) exposure [72]
  • Pronounced hallucinations, delirium, or agitation (suggesting a CNS effect) unresponsive to benzodiazepines
  • Intractable seizures resistant to all other treatments
  • Absence of QRS prolongation on ECG

Always have atropine at bedside when using physostigmine in order to reverse excessive cholinergic activity (eg, bradycardia, salivation).

Treat antihistamine-induced seizures with benzodiazepines and barbiturates. Reserve physostigmine for refractory seizures. Although case reports suggest that physostigmine ends seizures, clinical experience is limited and no proof of its efficacy for seizure control exists.

Neuroleptic agents, such as haloperidol, have been used but have anticholinergic effects and may exacerbate hyperthermia or provoke a dystonic reaction. Their use should be discouraged.

Manage hyperthermia, especially when severe agitation is present, with neuromuscular paralysis, evaporative cooling, and ice-bath immersion if temperature is higher than 105°F. Use of dantrolene or bromocriptine is controversial.

Sinus tachycardia usually does not require treatment. Sedation with a benzodiazepine may be helpful when agitation is also present. Intravenous (IV) sodium bicarbonate improves widening of QRS that may result from antihistamines with sodium channel blocking properties (eg, diphenhydramine, pyrilamine). Provide support for patients with profound cardiovascular toxicity. In rare cases of refractory shock, placement of an intra-aortic balloon pump for several hours may bridge the patient through a period of cardiovascular collapse.

The American Association of Poison Control Centers has issued evidence-based consensus guidelines on the out-of-hospital management of diphenhydramine and dimenhydrinate poisoning.[70]


Emergency Department Management

Ensure the patient has adequate airway, breathing, and circulation. Place the patient on a cardiorespiratory monitor and/or obtain intravenous (IV) access if the patient appears ill or is symptomatic. Administer oxygen, naloxone, and glucose if an unexplained decreased level of consciousness is observed.

Obtain the patient's history through a relative or emergency medical services (EMS) personnel. Examine the patient, looking for an anticholinergic toxidrome. Obtain appropriate lab tests and an ECG. Perform cardiac monitoring on all symptomatic patients or as long as tachycardia, conduction delays, or prolonged QT intervals persist.

Consider decontamination with activated charcoal. Treat acute dystonic reactions with benzodiazepines.

Provide other supportive measures. Consider hospital admission if ingestion is significant or if the patient continues to be symptomatic. Contact the regional poison control center.


Gastrointestinal Decontamination

Activated charcoal is the first-line defense in GI decontamination and should be given to the patient if a significant ingestion has occurred within recent hours before presentation. Activated charcoal is most effective if administered within 1 hour of ingestion.

Complications of activated charcoal administration include emesis and aspiration; consequently, patients should be cooperative, have a good gag reflex, and be able to take liquids by mouth safely. Patients with significant CNS depression require endotracheal intubation to secure the airway before administration of activated charcoal.

The optimal dose of charcoal is not well established. Usual doses are as follows:

  • Adults and adolescents: 25-100 g in adults and adolescents
  • Children aged 1-12 years: 25-50 g
  • Infants younger than 1 year: 1 g/kg

Multiple doses of activated charcoal are not recommended because charcoal concretions may form leading to intestinal obstruction or ileus. Antihistamines may induce intestinal ileus causing delayed absorption of drug and delayed toxicity.

Other methods of decontamination

Controversial methods of decontamination include gastric lavage and ipecac syrup. Use of these agents should be on the advice of a poison center or toxicologist.

Ipecac and gastric lavage have fallen into disfavor, and cathartic therapy is not recommended, especially in children. Emesis is not usually recommended and is specifically contraindicated if a depressed gag reflex, CNS depression, ingestion of a corrosive substance, or situation with high aspiration potential is noted.


Treatment of Dystonic Reactions

Dystonic reactions are treated with diphenhydramine in doses of 1 mg/kg IV every 2 minutes, with a maximum of 5 mg/kg/d, unless the dystonic reaction is thought to be caused by or involve antihistamine intoxication. Acute dystonic reactions to antihistamines may be treated with oral (PO) or IV diazepam. The dose is 0.1-0.3 mg/kg (slowly if IV) and as much as 10 mg in adults.


Treatment of Seizures

Seizures can be treated with lorazepam. The pediatric dose is 0.05-0.1 mg/kg, not to exceed 4 mg/dose; doses may be repeated every 10-15 minutes as needed. The adult dose is 4 mg, given by slow IV at 2 mg/min; if seizures persist after 10-15 minutes, administer 4 mg IV again. Monitor for hypotension, respiratory depression, and the need for endotracheal intubation. Case reports suggest that physostigmine may be effective for seizures refractory to benzodiazepines.


Treatment of Serotonin Syndrome

Serotonin syndrome must be managed by addressing each symptom individually. Hyperthermia should be managed by undressing the patient and enhancing evaporative heat loss by keeping the skin damp and using cooling fans. Muscle activity and agitation may be diminished with the use of diazepam.

Cyproheptadine is a nonspecific 5-hydroxytryptamine (5HT, serotonin) antagonist that has been shown to block development of serotonin syndrome in animals and is suggested as an antidote for serotonin syndrome in humans. It is available only as an oral preparation. Propranolol also has been used to some benefit as a 5HT1A receptor antagonist.


Treatment of Other Conditions

Cardiac arrhythmia can be managed with the appropriate cardiac medicine per advanced life support guidelines.[73] In diphenhydramine overdoses, bicarbonate may be helpful in treating QRS complex abnormalities and cardiac dysrhythmias. Treatment with bicarbonate in this overdose should be used in concert with poison center or medical toxicology consultation.

Rhabdomyolysis is managed by ensuring adequate hydration to maintain urine output at 2 mg/kg/h. Furosemide or mannitol may be needed to maintain diuresis. Consider using a solution of sodium bicarbonate and potassium chloride to alkalinize the urine to a pH of at least 7.5. Monitor serum pH to avoid inducing severe alkalemia. Chart strict intake and output. Consult a nephrologist for oliguria or renal failure, and arrange hemodialysis for the anuric or severely acidotic patient.

Muscle rigidity and hyperactivity are secondary to sympathomimetic toxicity and can be controlled with neuromuscular paralysis.

Hyperthermia associated with sympathomimetics can be controlled with external evaporative cooling, removing the patient's clothes, and spraying with tepid water and fanning.


Use of Physostigmine

Use of physostigmine in antihistamine poisoning is extremely controversial, and it should not be given unless directed by a regional poison control center or in direct consultation with a medical toxicologist. Physostigmine, an anticholinesterase, may be indicated in the suspected anticholinergic poisoning for its therapeutic value.

Physostigmine is a tertiary amine that crosses the blood brain barrier and reverses both the central and the peripheral effects of anticholinergics. Reversal of anticholinergic signs and symptoms is not long-lasting because physostigmine has a relatively short duration of action (20-60 min). Indications are severe life-threatening complications, such as coma, hypotension with dysrhythmias unresponsive to other attempts at treatment, and intractable seizures.

Adolescent and adult trial dosages are 2 mg IV slowly every 5 minutes. To administer, dilute the dose of physostigmine in 10 mL of dextrose 5% in water (D5W) or in 10 mL of isotonic sodium chloride solution.


Hospital Admission

Patients with suspected cough, cold, or allergy preparation poisoning with persistent or significant hypertension, dysrhythmia, or CNS stimulation require admission for monitoring. For all intentional overdoses, a psychiatric evaluation is necessary. The decision to admit the patient to the intensive care unit should be based on the following:

  • Initial presentation
  • Comorbid diseases
  • Nature and number of the involved agents
  • Potential for delayed toxicity


Medications should be labeled and stored safety. Child-resistant closures should be applied to all medications and substances that can cause significant toxicity, such as cough and cold medications. Childproof safety caps and clear labeling have been shown to decrease toxic exposures in young children and elderly individuals. Anticholinergics should not be used as sleep aids in elderly persons.


Consultations (replaces Diet)

The following consultations may be necessary:

  • Regional poison control center or a medical toxicologist as soon as possible
  • Intensivist for invasive monitoring and hemodynamic support in complicated cases
  • Nephrology service in the case of rhabdomyolysis and acute renal failure
  • Psychiatry for intentional overdoses
  • Neurology for neurologic complications

Long-Term Monitoring

Most regional poison control centers have their own protocols on who may be observed at home; contact them if ingestion has occurred. As a general rule, patients who ingest less than 3 times the maximum daily dose can be observed at home.

If symptoms are present (other than mild somnolence) or ingestion is more than 4 times the maximum daily dose, the patient should be referred to a health care fatained-release products may result in delayed onset of symptoms cility. The patient should be observed for 4-6 hours following ingestion of liquid and immediate-release solid preparations. Ingestion of susand may require longer periods of observation.

If the patient has ingested less than 10 mg/kg of dextromethorphan, the patient can be treated at home. If the patient has ingested a long-acting dextromethorphan, refer the patient to a health care facility for evaluation.

If the ingestion was intentional, prompt psychiatric evaluation and admission is warranted. Additional counseling and social work involvement may be required for patients engaging in recreational abuse.

Further outpatient treatment should include teaching the patient's caretaker about medication storage and safety.

Contributor Information and Disclosures

Laleh Gharahbaghian, MD Director, Emergency Ultrasound Program and Fellowship, Clinical Associate Professor, Department of Surgery, Division of Emergency Medicine, Stanford University Medical Center

Laleh Gharahbaghian, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.


Nicholas Lopez, MD Attending Physician, Department of Emergency Medicine, Queen of the Valley Medical Center, Sutter Solano Medical Center

Nicholas Lopez, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, Emergency Medicine Residents' Association

Disclosure: Nothing to disclose.

Chief Editor

Timothy E Corden, MD Associate Professor of Pediatrics, Co-Director, Policy Core, Injury Research Center, Medical College of Wisconsin; Associate Director, PICU, Children's Hospital of Wisconsin

Timothy E Corden, MD is a member of the following medical societies: American Academy of Pediatrics, Phi Beta Kappa, Society of Critical Care Medicine, Wisconsin Medical Society

Disclosure: Nothing to disclose.


Michael J Burns, MD Instructor, Department of Emergency Medicine, Harvard University Medical School, Beth Israel Deaconess Medical Center

Michael J Burns, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Emergency Physicians, American College of Medical Toxicology, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Loren Keith French, MD Attending Physician of Toxicology, Department of Emergency Medicine, Oregon Health and Sciences University and Oregon Poison Center

Disclosure: Nothing to disclose.

David C Lee, MD Research Director, Department of Emergency Medicine, Associate Professor, North Shore University Hospital and New York University Medical School

David C Lee, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Medical Toxicology, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Annette M Lopez, MD Toxicology Fellow, Oregon Health and Science University School of Medicine

Disclosure: Nothing to disclose.

David J McCann, MD Resident Physician, Department of Emergency Medicine, Harvard University Affiliated Emergency Medicine Residency Program, Harvard Medical School

Disclosure: Nothing to disclose.

Nathanael J McKeown, DO Assistant Professor, Department of Emergency Medicine, Oregon Health and Science University School of Medicine; Medical Toxicologist, Oregon Poison Center; Attending Physician, Emergency Medicine, Portland Veteran Affairs Medical Center

Nathanael J McKeown, DO is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Emergency Physicians, American College of Medical Toxicology, Society for Academic Emergency Medicine, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Jennifer A Oman, MD Associate Clinical Professor, Department of Emergency Medicine, University of California, Irvine, School of Medicine

Jennifer A Oman, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, Council of Emergency Medicine Residency Directors, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Brett Roth, MD  Assistant Professor, Department of Emergency Medicine, Division of Clinical Toxicology, University of Texas Southwestern Medical Center at Dallas, Southwestern Medical School

Disclosure: Nothing to disclose.

Anne Rutkowski, MD Resident Physician, Department of Emergency Medicine, Harbor-University of California at Los Angeles Medical Center

Disclosure: Nothing to disclose.

Asim Tarabar, MD Assistant Professor, Director, Medical Toxicology, Department of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital

Disclosure: Nothing to disclose.

Jeffrey R Tucker, MD Assistant Professor, Department of Pediatrics, Division of Emergency Medicine, University of Connecticut School of Medicine, Connecticut Children's Medical Center

Disclosure: Merck Salary Employment

John T VanDeVoort, PharmD Regional Director of Pharmacy, Sacred Heart and St Joseph's Hospitals

John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

  1. Jo YI, Song JO, Park JH, Koh SY, Lee SM, Seo TH, et al. Risk factors for rhabdomyolysis following doxylamine overdose. Hum Exp Toxicol. 2007 Aug. 26(8):617-21. [Medline].

  2. Vernacchio L, Kelly JP, Kaufman DW, Mitchell AA. Cough and cold medication use by US children, 1999-2006: results from the slone survey. Pediatrics. 2008 Aug. 122(2):e323-9. [Medline].

  3. US allergy market affecting the daily life of millions of Americans. Companies and Available at Accessed: August 21, 2013.

  4. Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000 Dec 21. 343(25):1826-32. [Medline].

  5. Spiller HA, Beuhler MC, Ryan ML, Borys DJ, Aleguas A, Bosse GM. Evaluation of changes in poisoning in young children: 2000 to 2010. Pediatr Emerg Care. 2013 May. 29(5):635-40. [Medline].

  6. Mazer-Amirshahi M, Reid N, van den Anker J, Litovitz T. Effect of Cough and Cold Medication Restriction and Label Changes on Pediatric Ingestions Reported to United States Poison Centers. J Pediatr. 2013 Jun 12. [Medline].

  7. Yin HS, Parker RM, Wolf MS, et al. Health literacy assessment of labeling of pediatric nonprescription medications: examination of characteristics that may impair parent understanding. Acad Pediatr. 2012 Jul-Aug. 12(4):288-96. [Medline].

  8. Smith SM, Schroeder K, Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev. 2012 Aug 15. 8:CD001831. [Medline].

  9. [Guideline] Bolser DC. Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines. Chest. 2006 Jan. 129(1 Suppl):238S-249S. [Medline]. [Full Text].

  10. Sharfstein JM, North M, Serwint JR. Over the counter but no longer under the radar--pediatric cough and cold medications. N Engl J Med. 2007 Dec 6. 357(23):2321-4. [Medline].

  11. Revised product labels for pediatric over-the-counter cough and cold medicines. MMWR Morb Mortal Wkly Rep. 2008 Oct 31. 57(43):1180. [Medline].

  12. [Guideline] Ostroff C, Lee CE, McMeekin J. Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications. Chest. 2011 Aug. 140(2):295-300. [Medline].

  13. Irwin RS, Baumann MH, Bolser DC, Boulet LP, Braman SS, Brightling CE, et al. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest. 2006 Jan. 129(1 Suppl):1S-23S. [Medline]. [Full Text].

  14. Yanai K, Rogala B, Chugh K, Paraskakis E, Pampura AN, Boev R. Safety considerations in the management of allergic diseases: focus on antihistamines. Curr Med Res Opin. 2012 Apr. 28(4):623-42. [Medline].

  15. Ly KS, Letavic MA, Keith JM, Miller JM, Stocking EM, Barbier AJ, et al. Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors. Bioorg Med Chem Lett. 2008 Jan 1. 18(1):39-43. [Medline].

  16. Sasho S, Seishi T, Kawamura M, Hirose R, Toki S, Shimada JI. Diamine derivatives containing imidazolidinylidene propanedinitrile as a new class of histamine H3 receptor antagonists. Part I. Bioorg Med Chem Lett. 2008 Apr 1. 18(7):2288-91. [Medline].

  17. Zhao C, Sun M, Bennani YL, Gopalakrishnan SM, Witte DG, Miller TR, et al. The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. J Med Chem. 2008 Sep 11. 51(17):5423-30. [Medline].

  18. Sasaki T, Takahashi T, Nagase T, Mizutani T, Ito S, Mitobe Y, et al. Synthesis, structure-activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H(3) receptor inverse agonists. Bioorg Med Chem Lett. 2009 Aug 1. 19(15):4232-6. [Medline].

  19. Covel JA, Santora VJ, Smith JM, Hayashi R, Gallardo C, Weinhouse MI, et al. Design and evaluation of novel biphenyl sulfonamide derivatives with potent histamine H(3) receptor inverse agonist activity. J Med Chem. 2009 Sep 24. 52(18):5603-11. [Medline].

  20. Josef KA, Aimone LD, Lyons J, Raddatz R, Hudkins RL. Synthesis of constrained benzocinnolinone analogues of CEP-26401 (irdabisant) as potent, selective histamine H3 receptor inverse agonists. Bioorg Med Chem Lett. 2012 Jun 15. 22(12):4198-202. [Medline].

  21. Stocking EM, Letavic MA. Histamine H3 antagonists as wake-promoting and pro-cognitive agents. Curr Top Med Chem. 2008. 8(11):988-1002. [Medline].

  22. Sander K, Kottke T, Stark H. Histamine H3 receptor antagonists go to clinics. Biol Pharm Bull. 2008 Dec. 31(12):2163-81. [Medline].

  23. Medhurst SJ, Collins SD, Billinton A, Bingham S, Dalziel RG, Brass A, et al. Novel histamine H3 receptor antagonists GSK189254 and GSK334429 are efficacious in surgically-induced and virally-induced rat models of neuropathic pain. Pain. 2008 Aug 15. 138(1):61-9. [Medline].

  24. Bembenek SD, Keith JM, Letavic MA, Apodaca R, Barbier AJ, Dvorak L, et al. Lead identification of acetylcholinesterase inhibitors-histamine H3 receptor antagonists from molecular modeling. Bioorg Med Chem. 2008 Mar 15. 16(6):2968-73. [Medline].

  25. Masaki T, Yoshimatsu H. Therapeutic approach of histamine H3 receptors in obesity. Recent Pat CNS Drug Discov. 2007 Nov. 2(3):238-40. [Medline].

  26. Deng C, Weston-Green K, Huang XF. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1. 34(1):1-4. [Medline].

  27. Beghdadi W, Porcherie A, Schneider BS, Morisset S, Dubayle D, Peronet R, et al. Histamine H(3) receptor-mediated signaling protects mice from cerebral malaria. PLoS One. 2009 Jun 23. 4(6):e6004. [Medline]. [Full Text].

  28. Alleva L, Tirelli E, Brabant C. Therapeutic potential of histaminergic compounds in the treatment of addiction and drug-related cognitive disorders. Behav Brain Res. 2013 Jan 15. 237:357-68. [Medline].

  29. Nuutinen S, Vanhanen J, Mäki T, Panula P. Histamine h3 receptor: a novel therapeutic target in alcohol dependence?. Front Syst Neurosci. 2012. 6:36. [Medline]. [Full Text].

  30. Bhowmik M, Khanam R, Vohora D. Histamine H3 receptor antagonists in relation to epilepsy and neurodegeneration: a systemic consideration of recent progress and perspectives. Br J Pharmacol. 2012 Dec. 167(7):1398-414. [Medline]. [Full Text].

  31. Vohora D, Bhowmik M. Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuse. Front Syst Neurosci. 2012. 6:72. [Medline]. [Full Text].

  32. Altenbach RJ, Adair RM, Bettencourt BM, Black LA, Fix-Stenzel SR, Gopalakrishnan SM, et al. Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands. J Med Chem. 2008 Oct 23. 51(20):6571-80. [Medline].

  33. Kiss R, Kiss B, Könczöl A, Szalai F, Jelinek I, László V, et al. Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. J Med Chem. 2008 Jun 12. 51(11):3145-53. [Medline].

  34. Tiligada E, Zampeli E, Sander K, Stark H. Histamine H3 and H4 receptors as novel drug targets. Expert Opin Investig Drugs. 2009 Oct. 18(10):1519-31. [Medline].

  35. Larbi EB. Drug-induced rhabdomyolysis. Ann Saudi Med. 1998 Nov-Dec. 18(6):525-30. [Medline].

  36. Pelle E, McCarthy J, Seltmann H, Huang X, Mammone T, Zouboulis CC, et al. Identification of histamine receptors and reduction of squalene levels by an antihistamine in sebocytes. J Invest Dermatol. 2008 May. 128(5):1280-5. [Medline].

  37. Devillier P, Roche N, Faisy C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008. 47(4):217-30. [Medline].

  38. De Vos C, Mitchev K, Pinelli ME, Derde MP, Boev R. Non-interventional study comparing treatment satisfaction in patients treated with antihistamines. Clin Drug Investig. 2008. 28(4):221-30. [Medline].

  39. Walsh GM. A review of the role of levocetirizine as an effective therapy for allergic disease. Expert Opin Pharmacother. 2008 Apr. 9(5):859-67. [Medline].

  40. Pinto YM, van Gelder IC, Heeringa M, Crijns HJ. QT lengthening and life-threatening arrhythmias associated with fexofenadine. Lancet. 1999 Mar 20. 353(9157):980. [Medline]. [Full Text].

  41. Scherer CR, Lerche C, Decher N, Dennis AT, Maier P, Ficker E, et al. The antihistamine fexofenadine does not affect I(Kr) currents in a case report of drug-induced cardiac arrhythmia. Br J Pharmacol. 2002 Nov. 137(6):892-900. [Medline]. [Full Text].

  42. Giraud T. QT lengthening and arrhythmias associated with fexofenadine. Lancet. 1999 Jun 12. 353(9169):2072-3. [Medline]. [Full Text].

  43. Soldovieri MV, Miceli F, Taglialatela M. Cardiotoxic effects of antihistamines: from basics to clinics (...and back). Chem Res Toxicol. 2008 May. 21(5):997-1004. [Medline].

  44. Izumi N, Mizuguchi H, Umehara H, Ogino S, Fukui H. Analysis of disease-dependent sedative profiles of H(1)-antihistamines by large-scale surveillance using the visual analog scale. Methods Find Exp Clin Pharmacol. 2008 Apr. 30(3):225-30. [Medline].

  45. Hishinuma S, Sato Y, Kobayashi Y, Komazaki H, Saito M. Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May. 107(1):66-79. [Medline].

  46. Obradovic T, Dobson GG, Shingaki T, Kungu T, Hidalgo IJ. Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein. Pharm Res. 2007 Feb. 24(2):318-27. [Medline].

  47. de Leon J, Nikoloff DM. Paradoxical excitation on diphenhydramine may be associated with being a CYP2D6 ultrarapid metabolizer: three case reports. CNS Spectr. 2008 Feb. 13(2):133-5. [Medline].

  48. Lucero ML, Arteche JK, Sommer EW, Casadesus A. Preclinical toxicity profile of oral bilastine. Drug Chem Toxicol. 2012 Jun. 35 Suppl 1:25-33. [Medline].

  49. Bektas F, Eken C, Oktay C. Pseudoephedrine-induced paroxysmal supraventricular tachycardia: a case report. J Emerg Med. 2010 Jun. 38(5):e53-7. [Medline].

  50. Bilici M, Turkay S, Yilmaz AE, Kurtaran H, Catal F, Tonbul A, et al. Effect of pseudoephedrine on cardiac rhythm of children with rhinitis. Indian J Pediatr. 2011 Nov. 78(11):1361-4. [Medline].

  51. American Hospital Association (AHA) Annual Survey Database,. Fiscal Year 2003. Health Forum LLC,. One North Franklin Street, Chicago, IL 60606: Copyright 2003, .

  52. Bryner JK, Wang UK, Hui JW, Bedodo M, MacDougall C, Anderson IB. Dextromethorphan abuse in adolescence: an increasing trend: 1999-2004. Arch Pediatr Adolesc Med. 2006 Dec. 160(12):1217-22. [Medline]. [Full Text].

  53. Flynn CA, Griffin GH, Schultz JK. WITHDRAWN: Decongestants and antihistamines for acute otitis media in children. Cochrane Database Syst Rev. 2007 Jul 18. CD001727. [Medline].

  54. Mowry JB, Spyker DA, Brooks DE, McMillan N, Schauben JL. 2014 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 32nd Annual Report. Clin Toxicol (Phila). 2015 Dec. 53 (10):962-1147. [Medline].

  55. Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Dart RC. 2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol (Phila). 2011 Dec. 49(10):910-41. [Medline]. [Full Text].

  56. Sen A, Akin A, Craft KJ, Canfield DV, Chaturvedi AK. First-generation H1 antihistamines found in pilot fatalities of civil aviation accidents, 1990-2005. Aviat Space Environ Med. 2007 May. 78(5):514-22. [Medline].

  57. Guide for Aviation Medical Examiners: Pharmaceuticals (Therapeutic Medications) Allergy-Antihistimines. Federal Aviation Administration; October 24, 2012. 207. Available at

  58. Kamijo Y, Soma K, Sato C, Kurihara K. Fatal diphenhydramine poisoning with increased vascular permeability including late pulmonary congestion refractory to percutaneous cardiovascular support. Clin Toxicol (Phila). 2008 Nov. 46(9):864-8. [Medline].

  59. Matsunaga C, Izumi S, Furukubo T, Satoh M, Yamakawa T, Uchida T, et al. Effect of famotidine and lansoprazole on serum phosphorus levels in hemodialysis patients on calcium carbonate therapy. Clin Nephrol. 2007 Aug. 68(2):93-8. [Medline].

  60. Karpa KD, Felix TM, Lewis PR. Adverse Effects of Common Drugs: Children and Adolescents. FP Essent. 2015 Sep. 436:17-22. [Medline].

  61. Yang M, So TY. Revisiting the safety of over-the-counter cough and cold medications in the pediatric population. Clin Pediatr (Phila). 2014 Apr. 53 (4):326-30. [Medline].

  62. Birring SS, Kavanagh J, Lai K, Chang AB. Adult and paediatric cough guidelines: Ready for an overhaul?. Pulm Pharmacol Ther. 2015 Feb 11. [Medline].

  63. Tashiro M, Sakurada Y, Mochizuki H, Horikawa E, Maruyama M, Okamura N, et al. Effects of a sedative antihistamine, D-chlorpheniramine, on regional cerebral perfusion and performance during simulated car driving. Hum Psychopharmacol. 2008 Mar. 23(2):139-50. [Medline].

  64. Bebarta VS, Blair HW, Morgan DL, Maddry J, Borys DJ. Validation of the American Association of Poison Control Centers out of hospital guideline for pediatric diphenhydramine ingestions. Clin Toxicol (Phila). 2010 Jul. 48(6):559-62. [Medline].

  65. Tobin JR, Doyle TP, Ackerman AD, Brenner JI. Astemizole-induced cardiac conduction disturbances in a child. JAMA. 1991 Nov 20. 266(19):2737-40. [Medline].

  66. Nine JS, Rund CR. Fatality from diphenhydramine monointoxication: a case report and review of the infant, pediatric, and adult literature. Am J Forensic Med Pathol. 2006 Mar. 27(1):36-41. [Medline].

  67. Mendoza FS, Atiba JO, Krensky AM, Scannell LM. Rhabdomyolysis complicating doxylamine overdose. Clin Pediatr (Phila). 1987 Nov. 26(11):595-7. [Medline].

  68. Cravo M, Gonçalo M, Figueiredo A. Fixed drug eruption to cetirizine with positive lesional patch tests to the three piperazine derivatives. Int J Dermatol. 2007 Jul. 46(7):760-2. [Medline].

  69. Köppel C, Ibe K, Tenczer J. Clinical symptomatology of diphenhydramine overdose: an evaluation of 136 cases in 1982 to 1985. J Toxicol Clin Toxicol. 1987. 25(1-2):53-70. [Medline].

  70. Feldman MD, Behar M. A case of massive diphenhydramine abuse and withdrawal from use of the drug. JAMA. 1986 Jun 13. 255(22):3119-20. [Medline].

  71. Gupta SK, Kantesaria B, Wang Z. Multiple-dose pharmacokinetics and safety of desloratadine in subjects with moderate hepatic impairment. J Clin Pharmacol. 2007 Oct. 47(10):1283-91. [Medline].

  72. Frascogna N. Physostigmine: is there a role for this antidote in pediatric poisonings?. Curr Opin Pediatr. 2007 Apr. 19(2):201-5. [Medline].

  73. [Guideline] Pediatric basic and advanced life support. 2005 International Consensus Conference on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Circulation. 2005 Nov 29. 112(22 Suppl); III73-90.

  74. Haase U, Rundshagen I. [Pharmacotherapy--physostigmine administered post-operatively]. Anasthesiol Intensivmed Notfallmed Schmerzther. 2007 Mar. 42(3):188-9. [Medline].

  75. Hulhoven R, Rosillon D, Letiexhe M, Meeus MA, Daoust A, Stockis A. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur J Clin Pharmacol. 2007 Nov. 63(11):1011-7. [Medline].

  76. Janssens F, Leenaerts J, Diels G, De Boeck B, Megens A, Langlois X, et al. Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines. J Med Chem. 2005 Mar 24. 48(6):2154-66. [Medline].

  77. Kabat-Koperska J, Safranow K, Golembiewska E, Domanski L, Ciechanowski K. Creatinine clearance after cimetidine administration: is it useful in the monitoring of the function of transplanted kidney?. Ren Fail. 2007. 29(6):667-72. [Medline].

  78. Lassaletta A, Martino R, Gónzalez-Santiago P, Torrijos C, Cebrero M, García-Frías E. Reversal of an antihistamine-induced coma with flumazenil. Pediatr Emerg Care. 2004 May. 20(5):319-20. [Medline].

  79. [Guideline] Scharman EJ, Erdman AR, Wax PM, Chyka PA, Caravati EM, Nelson LS, et al. Diphenhydramine and dimenhydrinate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2006. 44(3):205-23. [Medline].

  80. Serio RN. Acute delirium associated with combined diphenhydramine and linezolid use. Ann Pharmacother. 2004 Jan. 38(1):62-5. [Medline].

  81. Simons FE. Safety of levocetirizine treatment in young atopic children: An 18-month study. Pediatr Allergy Immunol. 2007 Sep. 18(6):535-42. [Medline].

  82. Stojanovski SD, Baker SD, Casavant MJ, Hayes JR, Robinson RF, Nahata MC. Implications of diphenhydramine single-dose unintended ingestions in young children. Pediatr Emerg Care. 2007 Jul. 23(7):465-8. [Medline].

  83. Sype JW, Khan IA. Prolonged QT interval with markedly abnormal ventricular repolarization in diphenhydramine overdose. Int J Cardiol. 2005 Mar 18. 99(2):333-5. [Medline].

  84. Thakur AC, Aslam AK, Aslam AF, Vasavada BC, Sacchi TJ, Khan IA. QT interval prolongation in diphenhydramine toxicity. Int J Cardiol. 2005 Feb 15. 98(2):341-3. [Medline].

  85. Yamaura K, Shigemori A, Suwa E, Ueno K. Expression of the histamine H4 receptor in dermal and articular tissues. Life Sci. 2013 Feb 7. 92(2):108-13. [Medline].

Terfenadine is the antihistamine most commonly associated with torsade de pointes in both acute overdose and therapeutic administration.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.